Neoleukin Therapeutics (NLTX) Competitors $21.45 -0.27 (-1.24%) As of 08/5/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NLTX vs. IMTX, CRMD, PROK, OCS, XERS, CRON, ANAB, UPB, GHRS, and NAGEShould you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Immatics (IMTX), CorMedix (CRMD), ProKidney (PROK), Oculis (OCS), Xeris Biopharma (XERS), Cronos Group (CRON), AnaptysBio (ANAB), Upstream Bio (UPB), GH Research (GHRS), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry. Neoleukin Therapeutics vs. Its Competitors Immatics CorMedix ProKidney Oculis Xeris Biopharma Cronos Group AnaptysBio Upstream Bio GH Research Niagen Bioscience Immatics (NASDAQ:IMTX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment. Which has more risk & volatility, IMTX or NLTX? Immatics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Do analysts recommend IMTX or NLTX? Immatics presently has a consensus target price of $14.67, indicating a potential upside of 131.34%. Given Immatics' stronger consensus rating and higher probable upside, analysts clearly believe Immatics is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immatics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals hold more shares of IMTX or NLTX? 64.4% of Immatics shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is IMTX or NLTX more profitable? Neoleukin Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -14.73%. Immatics' return on equity of -4.52% beat Neoleukin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Immatics-14.73% -4.52% -3.34% Neoleukin Therapeutics N/A -37.22%-30.91% Does the media prefer IMTX or NLTX? In the previous week, Immatics had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for Immatics and 0 mentions for Neoleukin Therapeutics. Immatics' average media sentiment score of 0.00 equaled Neoleukin Therapeutics'average media sentiment score. Company Overall Sentiment Immatics Neutral Neoleukin Therapeutics Neutral Which has stronger earnings and valuation, IMTX or NLTX? Immatics has higher revenue and earnings than Neoleukin Therapeutics. Immatics is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmatics$168.65M4.57$16.47M-$0.17-37.29Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-6.90 SummaryImmatics beats Neoleukin Therapeutics on 11 of the 15 factors compared between the two stocks. Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLTX vs. The Competition Export to ExcelMetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$201.59M$784.23M$5.50B$9.55BDividend YieldN/A4.84%4.71%4.14%P/E Ratio-6.901.3028.7823.91Price / SalesN/A27.01438.3895.11Price / CashN/A19.5635.6858.35Price / Book1.946.598.225.62Net Income-$57.56M-$4.20M$3.25B$265.35M7 Day Performance-1.06%-4.48%-0.73%-0.89%1 Month Performance6.77%-0.96%5.52%4.98%1 Year Performance-41.71%18.29%28.79%23.50% Neoleukin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLTXNeoleukin TherapeuticsN/A$21.45-1.2%N/A-45.1%$201.59MN/A-6.9090High Trading VolumeIMTXImmatics2.1905 of 5 stars$6.61-0.9%$14.67+121.9%-41.4%$803.45M$144.15M-38.88260News CoverageUpcoming EarningsCRMDCorMedix2.5775 of 5 stars$11.79-1.6%$17.14+45.4%+197.0%$798.58M$43.47M53.5330News CoveragePositive NewsUpcoming EarningsPROKProKidney3.1845 of 5 stars$2.72-11.7%$6.25+129.8%+76.7%$797.61M$80K-4.543Upcoming EarningsOCSOculis3.0405 of 5 stars$18.08+1.0%$35.33+95.5%+53.3%$789.15M$780K-6.852XERSXeris Biopharma3.6407 of 5 stars$5.05-0.5%$6.25+23.9%+145.7%$788.94M$203.07M-16.82290Upcoming EarningsShort Interest ↑CRONCronos Group2.6719 of 5 stars$2.02-2.2%N/A-5.9%$777.15M$117.61M15.50450Upcoming EarningsANABAnaptysBio2.4679 of 5 stars$26.45-0.5%$47.13+78.2%-26.8%$776.95M$91.28M-5.45100Positive NewsEarnings ReportUPBUpstream Bio1.7515 of 5 stars$14.36+0.1%$56.50+293.5%N/A$770.27M$2.37M0.0038News CoverageEarnings ReportGap DownGHRSGH Research2.2551 of 5 stars$14.80-1.2%$32.00+116.3%+14.1%$769.78MN/A-18.7310Positive NewsNAGENiagen Bioscience1.0341 of 5 stars$9.58-1.1%$13.22+38.0%N/A$754.62M$99.60M56.35120News CoverageEarnings Report Related Companies and Tools Related Companies Immatics Alternatives CorMedix Alternatives ProKidney Alternatives Oculis Alternatives Xeris Biopharma Alternatives Cronos Group Alternatives AnaptysBio Alternatives Upstream Bio Alternatives GH Research Alternatives Niagen Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLTX) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredDebt Crisis Warning: How to Protect Your Wealth Before August 31stOn August 31st, the U.S. runs out of “extraordinary measures” to avoid default—and Washington insiders are alr...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
